CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 25,044,956	$ 18,559,130
Short-term investments	141,747,724	78,912,297
Receivables	25,790	273,044
Prepaid expenses	1,564,385	751,255
Other assets	178,374	77,077
Total current assets	168,561,229	98,572,803
Property and equipment, net	1,745,806	2,182,399
Other noncurrent assets	1,861,770	7,067
Total assets	172,168,805	100,762,269
Current liabilities:
Accounts payable	1,323,324	376,394
Accrued wages and benefits	2,120,901	2,533,133
Accrued clinical trial expenses	1,053,650	689,985
Accrued expenses and other liabilities	1,455,953	946,668
Total current liabilities	5,953,828	4,546,180
Deferred revenue, net of current portion	348,800	731,944
Total liabilities	6,302,628	5,278,124
Stockholders’ equity:
Common stock: $0.001 par value, 100,000,000 shares authorized; 48,203,529 and 69,996,070 shares issued and outstanding at December 31, 2017 and June 30, 2018	69,996	48,204
Additional paid-in capital	494,612,923	404,454,909
Accumulated other comprehensive loss	(34,324)	(64,433)
Retained deficit	(328,782,418)	(308,954,535)
Total stockholders’ equity	165,866,177	95,484,145
Total liabilities and stockholders’ equity	$ 172,168,805	$ 100,762,269